(R)-(+)- and (S)-(−)-ifosfamide (top),
|Trade names||Ifex, others|
|Elimination half-life||60–80% in 72 hours|
|Chemical and physical data|
|Molar mass||261.1 g mol−1|
|3D model (JSmol)|
Ifosfamide (IFO), sold under the brand name Ifex among others, is a chemotherapy medication used to treat a number of types of cancer. This includes testicular cancer, soft tissue sarcoma, osteosarcoma, bladder cancer, small cell lung cancer, cervical cancer, and ovarian cancer. It given by injection into a vein.
Common side effects include hair loss, vomiting, blood in the urine, infections, and kidney problems. Other severe side effects include bone marrow suppression and decreased level of consciousness. Use during pregnancy will likely result in harm to the baby. Ifosfamide is in the alkylating agent and nitrogen mustard family of medications. It works by disrupting the duplication of DNA and the creation of RNA.
Ifosfamide was approved for medical use in the United States in 1987. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 7.35 to 70.70 USD per 2 gm vial. In the UK this dose costs the NHS about 130.04 pounds.
It is given as a treatment for a variety of cancers, including:
- Testicular cancer
- Breast cancer
- Lymphoma (Hodgkin and non-Hodgkin)
- Soft tissue sarcoma
- Osteosarcoma or bone tumor
- Lung cancer
- Cervical cancer
- Ovarian cancer
Ifosfamide is given quickly, and in some cases can be given as quickly as an hour.
Hemorrhagic cystitis is rare when ifosfamide is given with mesna. A common and dose-limiting side effect is encephalopathy (brain dysfunction). It occurs in some form in up to 50% of people receiving the agent. The reaction is probably mediated by chloroacetaldehyde, one of the breakdown products of the ifosfamide molecule, which has chemical properties similar to acetaldehyde and chloral hydrate. The symptoms of ifosfamide encephalopathy can range from mild (difficulty concentrating, fatigue), to moderate (delirium, psychosis), to severe (nonconvulsive status epilepticus or coma). In children, this can interfere with neurological development. Apart from the brain, ifosfamide can also affect peripheral nerves. The severity of the reaction can be classified according to either the National Cancer Institute or the Meanwell criteria (grade I-IV). Previous brain problems and low levels of albumin in the blood increase the likelihood of ifosfamide encephalopathy. In most cases, the reaction resolves spontaneously within 72 hours. If it develops during an infusion of the drug, discontinuing the infusion is advised. The most effective treatment for severe (grade III-IV) encephalopathy is an intravenous solution of methylene blue, which appears to shorten the duration of encephalopathy; the exact mechanism of action of methylene blue is unclear. In some cases, methylene blue may be used as a prophylaxis before further doses of ifosfamide are administered. Other treatments include albumin and thiamine, and dialysis as a rescue modality.
- "Ifosfamide". The American Society of Health-System Pharmacists. Archived from the original on 7 May 2017. Retrieved 8 December 2016.
- Dowd, Frank J.; Johnson, Bart; Mariotti, Angelo (2016). Pharmacology and Therapeutics for Dentistry (7 ed.). Elsevier Health Sciences. p. 533. ISBN 9780323445955. Archived from the original on 2017-09-11.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Ifosfamide". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 580. ISBN 9780857111562.
- Ajithkumar T, Parkinson C, Shamshad F, Murray P (March 2007). "Ifosfamide encephalopathy". Clin Oncol (R Coll Radiol). 19 (2): 108–14. doi:10.1016/j.clon.2006.11.003. PMID 17355105.
- Foster, Corey, ed. (2010). The Washington Manual of Therapeutics (33 ed.). Wolters Kluwer | Lippincott Williams & Wilkins. p. 407.